Search this site:

About CET

CET specializes in stem cell research, tissue engineering and cancer biology. We develop media, provide and conduct research on stem cells obtained from human non-embryonic sources, such as adipose tissue, bone marrow, Wharton’s jelly, umbilical cord blood, and placentas. In addition, CET's mission is to be a leading provider of induced pluripotent (IPS) stem cells derived from normal human volunteers and patients with various clinical conditions. Our engineering focus is on preclinical drug discovery and high throughput drug screening and discovery applications for various human diseases. CET's cancer biology focus is on the isolation and culture of solid tumors from cancers of the breast, colon, kidney, lung and prostate.
Alan Moy, MD     Chief Executive Officer and Founder

Alan Moy, M.D., a physician-scientist, was previously on faculty for 13 years at the University of Iowa Department of Internal Medicine and Biomedical Engineering.  Dr. Moy founded the company in 2000. Dr. Moy received a Bachelor's degree in Biochemistry from the University of California, Davis and an M.D. from Creighton University.  He received postgraduate education in Internal Medicine from St. Louis University and completed a fellowship in Pulmonary Medicine and Critical Care Medicine at the University of Iowa. Dr. Moy's research expertise is in the area of vascular biology and tissue engineering. Dr. Moy is also listed in the 2010 Who's Who in America and is listed in 2011 as a Leading Physician of the World by the International Association of Healthcare Professions.


Social Media Links:

YouTube Facebook Twitter